id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-0687-0007,FDA,FDA-2013-E-0687,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-12-29T05:00:00Z,2016,12,2016-12-29T05:00:00Z,,2016-12-29T17:16:50Z,,0,0,090000648243df84
FDA-2013-E-0687-0006,FDA,FDA-2013-E-0687,180 Day Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-19T05:00:00Z,2015,11,2015-11-19T05:00:00Z,,2015-11-19T14:26:09Z,,0,0,0900006481d5a6ff
FDA-2013-E-0687-0005,FDA,FDA-2013-E-0687,"Determination of Regulatory Review Period for Purposes of Patent
Extension; AUBAGIO—Patent No. 6,794,410",Notice,Determinations,2015-04-15T04:00:00Z,2015,4,2015-04-15T04:00:00Z,2015-10-14T03:59:59Z,2015-04-15T14:13:14Z,2015-08616,0,0,0900006481aa67d0
FDA-2013-E-0687-0004,FDA,FDA-2013-E-0687,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2014-07-16T04:00:00Z,2014,7,2014-07-16T04:00:00Z,,2014-07-16T18:35:37Z,,0,0,09000064817b217b
FDA-2013-E-0687-0003,FDA,FDA-2013-E-0687,Letter from FDA CDER to U.S. Patent and trademark Office,Other,Letter(s),2014-01-31T05:00:00Z,2014,1,2014-01-31T05:00:00Z,,2014-01-31T15:17:21Z,,0,0,0900006481539700
FDA-2013-E-0687-0002,FDA,FDA-2013-E-0687,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-06-07T04:00:00Z,2013,6,2013-06-07T04:00:00Z,,2013-06-07T18:51:26Z,,0,0,0900006481313fbd
FDA-2013-E-0687-0001,FDA,FDA-2013-E-0687,"Aventis Pharmaceuticals, Inc. - Patent Extension Application",Other,Application,2013-06-07T04:00:00Z,2013,6,2013-06-07T04:00:00Z,,2013-06-07T18:51:26Z,,0,0,0900006481313efa